Related Experiment Video
Updated: Jun 7, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Current problems in hypertension and nephrology
Insights
This review discusses key challenges and controversies in hypertension and nephrology, focusing on European Society of Hypertension guidelines. It covers treatment strategies, dyslipidemia management, and cardiovascular risk reduction in chronic kidney disease patients.
Area of Science:
- Pharmacotherapy
- Nephrology
- Cardiovascular Medicine
Background:
- This issue addresses critical and debated topics in hypertension and nephrology.
- It examines the 2009 European Society of Hypertension (ESH) recommendations.
Discussion:
- Key aspects include beta-blocker use, combined therapy with ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), and hypertension management in elderly patients.
- The role of destiffening therapy and dyslipidemia management in hypertensive and chronic kidney disease (CKD) patients are also discussed.
Key Insights:
- New strategies for preventing cardiovascular risk in CKD patients are presented.
- Optimal blood pressure targets and nephroprotective hypotensive drugs for hypertensive nephropathy are evaluated.
Outlook:
- While not exhaustive, this issue provides valuable insights into current challenges in hypertension and nephrology.
- It aims to be an interesting and useful resource for healthcare professionals.
Abstract:
The aim of this issue of Expert Opinion on Pharmacotherapy is to present the most important and controversial problems in hypertension and nephrology. To this end, the most important points of the current (2009) recommendations of the European Society of Hypertension (ESH) are discussed, including aspects related to the treatment of hypertension - the role of beta-blockers, combined therapy with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) the treatment of hypertension in elderly patients, and role of destiffening therapy. The authors also present current recommendations for the management of dyslipidemia in hypertensive and chronic kidney disease (CKD) patients, and new strategies to prevent cardiovascular risk in CKD patients, the optimal level of blood pressure in patients with hypertensive nephropathy and which hypotensive drugs are the most nephroprotective. The Editors are aware that many other important problems have not been addressed in this issue of the journal; however, they hope the readers find it interesting and useful.
Related Concept Videos
Hypertension V: Nursing Management
Hypertension and Regulation of Blood Pressure
Hypertension II: Pathophysiology
Chronic Kidney Disease IV: Nursing Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension I: Introduction
